One thing the Euro trial demonstrated was a dose dependent response. I think that is hard to get by chance.I always knew it was going to be difficult to prove cognition in the earlier stage IMAGINE trial patients in just 12 months, but plaque removal was supposed to be the safe endpoint.
Short term it is now up to the extension trial to show some effect.
An example of the difficulty with reaching stat sig in such a small trial are the LLY EXPEDITION1 & EXPEDITION2 Sola trials. with around 1000 patients in each, and over 18 months, each trial failed to prove primary endpoints. When they combined both trials they were able to demonstrate significance in an early stage subgroup of slowing cognition loss.
https://investor.lilly.com/releasedetail2.cfm?ReleaseID=702211
Prana tried it with just 42 patients.
Another example to take from the EXPEDITION trials is that with all their resources, LLY were not able to release further analysis till over a month after top line results were released. Investors expecting Prana to release more in just a few weeks is perhaps not realistic. LLY topline results were Aug24 and further info was not released till Oct 8, about 6 weeks later.
https://investor.lilly.com/releasedetail.cfm?ReleaseID=726309
There is little doubt the IMAGINE trial is the abnormality, because no other trials have reported plaque reduction from the placebo arm.
Forgetting the placebo abnormal result, PBT2 did reduce plaque from baseline.
- Forums
- ASX - By Stock
- kempler on abc tonight on the business
One thing the Euro trial demonstrated was a dose dependent...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $34 | 10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 17196248 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 130790145 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 17196248 | 0.003 |
64 | 88003179 | 0.002 |
28 | 140710099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 129653155 | 26 |
0.005 | 18848455 | 22 |
0.006 | 22089363 | 18 |
0.007 | 54073650 | 25 |
0.008 | 42418463 | 31 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |